Introduction
============

Malignant mixed Müllerian tumor (MMMT) is an uncommon tumor in females and the occurrence of this disease outside the genital tract is extremely rare. In a review of the English literature since 1955, only 48 cases of extragenital MMMT have been reported other than the presented case. Sixteen out of these 49 (32.7%) extragenital MMMTs \[[@B1]\], including this case, were associated with synchronous or metachronous colonic cancer or gynecologic malignancy and serous carcinoma of the peritoneum (Table [1](#T1){ref-type="table"}). The MMMT often presents in elderly menopausal women and is a highly aggressive tumor. We report the clinical course and pathologic findings of an extragenital MMMT arising from the mesorectum in a perimenopausal woman and a review of the English literature.

###### 

Previous reports of malignant mixed Müllerian tumor (MMMT) with synchronous or metachronous neoplasm

  Case            Year   Author                     Age   Primary site                 Tissue type    Associated tumor                                    Treatment                                                              Prognosis
  --------------- ------ -------------------------- ----- ---------------------------- -------------- --------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------
  1 \[[@B15]\]    1983   Hermann and Tessler        72    Abdominal retroperitoneum    Heterologous   Ovarian serous papillary carcinoma, metachronous    Operation, CT (Adriamycin (doxorubicin), cytoxan, DTIC, vincristine)   Death at six months
                                                                                                                                                                                                                                 
  2 \[[@B16]\]    1988   Chen and Wolk              58    Pelvic peritoneum            Homologous     Ovarian serous papillary carcinoma, metachronous    Operation, RT                                                          Death at 11 months
                                                                                                                                                                                                                                 
  3 \[[@B17]\]    1989   El-Jabbour *et al.*        76    Ascending colon peritoneum   Heterologous   Colonic adenocarcinoma, synchronous                 Operation                                                              Death at 14 days
                                                                                                                                                                                                                                 
  4 \[[@B18]\]    1991   Garde and Jones *et al.*   65    Diaphragmatic peritoneum     Heterologous   Ovarian endometrioid adenocarcinoma, metachronous   Operation, CT (Adriamycin (doxorubicin), cisplatin, ifosfamide)        Death at six months
                                                                                                                                                                                                                                 
  5 \[[@B19]\]    1991   Solis *et al.*             54    Pelvic peritoneum            Heterologous   Serous carcinoma of peritoneum, synchronous         Operation, CT (Adriamycin (doxorubicin), cisplatin, cytoxan)           Unknown
                                                                                                                                                                                                                                 
  6 \[[@B9]\]     1994   Garamvoelgyi *et al.*      59    Pelvic peritoneum            Heterologous   Endometrial adenocarcinoma, metachronous            Operation, CT ( ifosfamide)                                            Death at 24 months
                                                                                                                                                                                                                                 
  7 \[[@B9]\]     1994   Garamvoelgyi *et al.*      64    Pelvic peritoneum            Homologous     Fallopian tube cacinoma in situ, synchronous        Operation                                                              Death at eight months
                                                                                                                                                                                                                                 
  8 \[[@B9]\]     1994   Garamvoelgyi *et al.*      84    Retrouterine peritoneum      Heterologous   Colonic adenocarcinoma, synchronous                 Operation                                                              Death at two months from heart disease
                                                                                                                                                                                                                                 
  9 \[[@B20]\]    1995   Mira *et a*l.              62    Pelvic peritoneum            Heterologous   Ovarian endometrioid adenocarcinoma, metachronous   Operation                                                              Survival for 28 months
                                                                                                                                                                                                                                 
  10 \[[@B21]\]   1997   Rose *et al.*              71    Peritoneum                   Homologous     Uterine cervical adenocarcinoma, synchronous        Operation, CT (cisplatin, ifosfamide)                                  Death at six months
                                                                                                                                                                                                                                 
  11 \[[@B22]\]   2001   Shen *et al.*              33    Pelvic peritoneum            Heterologous   Endometrial adenocarcinoma, metachronous            Operation                                                              Death at 12 months
                                                                                                                                                                                                                                 
  12 \[[@B22]\]   2001   Shen *et al.*              40    Pelvic                       Heterologous   Fallopian tube carcinoma, metachronous              Operation                                                              Unknown
                                                                                                                                                                                                                                 
  13 \[[@B23]\]   2005   Mikami *et al.*            53    Mesentery                    Heterologous   Fallopian tube carcinoma, metachronous              Operation, CT                                                          Survival for six months
                                                                                                                                                                                                                                 
  14 \[[@B24]\]   2005   Shaco-Levy                 85    Omentum                      Heterologous   Colonic adenocarcinoma, metachronous                Operation                                                              Survival for three months
                                                                                                                                                                                                                                 
  15 \[[@B1]\]    2006   Ma *et al.*                62    Mesentery                    Homologous     Ovarian adenocarcinofibroma, synchronous            Operation, CT (ifosfamide, carboplatin, etoposide)                     Death at 30 months
                                                                                                                                                                                                                                 
  16              2008   Current case               50    Mesentery                    Homologous     Ovarian adenocarcinoma, synchronous                 Operation                                                              Death at 10 months

CT, computed tomography; DTIC, Dacarbazine; RT, radiotherapy

Case presentation
=================

The patient case was a 50-year-old, gravid 0, para 0 (G0P0), unmarried Han Chinese woman with regular menstruation. Six months ago, she visited another medical center in Southern Taiwan for abdominal bloating, where bilateral ovarian tumors were diagnosed. At laparotomy, a left ovarian cystic tumor (35 × 20 × 10 cm) and a right ovarian tumor (12 × 8.5 × 6 cm) with normal uterus and cervix were noted. An additional tumor of about 12 × 9 × 8 cm in size was also found in the mesorectum of the rectosigmoid colon. Resection of the mesorectum and bilateral oophorectomy was performed at the first operation at another medical center. The histopathology report revealed bilateral ovarian cancer (endometrioid adenocarcinoma) and malignant mixed Müllerian tumor from the mesorectum with biphasic differentiation (adenocarcinomatous and spindle cell sarcomatous elements). No heterologous element was identified. No further treatment was performed after the first time of operation. However, she felt progressive abdominal bloating and dysuria recently. She, therefore, visited the department of surgery of our hospital. On physical examination a lower abdominal mass was palpated. An abdominal computed tomography scan revealed a large low density mass in the pelvic cavity (Figure [1](#F1){ref-type="fig"}). The maximum size of this lesion was about 15 cm in its long-axis diameter. This mass affected the bladder and the rectosigmoid colon. Laboratory tests showed that the serum lactate dehydrogenase level was 271 IU/L. The serum CA 125 level was elevated up to 154.3 U/mL, while the serum CA19-9 level was within the normal range.

![**A large low-density mass lesion was noted in the pelvic cavity and a significant mass effect at rectosigmoid and bladder was also noted (arrow)**.](1752-1947-5-15-1){#F1}

On suspicion of the recurrence of a tumor, another laparotomy was performed. The pelvic cavity was fully occupied by a huge cystic mass with adjacent organ involvement. A tumor measuring 12 × 10 × 8 cm arising from the mesorectum was identified - the terminal ileum was also involved. The tumor infiltrated into the pelvic floor and the retroperitoneum and a palliative resection of the rectosigmoid colon with an end-to-end anastomosis was performed. Unfortunately, 10 days later, the patient had an anastomotic leakage caused by the penetration of the drain tube which was noted when a colonoscopy was performed. Consequently, an ileostomy was constructed for fecal diversion as the healing of the leakage site had failed. The pathologic findings showed neoplastic cells with areas of local glandular and squamoid differentiation. In addition, bizarre giant tumor cells in the carcinoma component were also noted (Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). Patternless oval to spindled neoplastic cells were noted in the sarcoma component (Figure [2C](#F2){ref-type="fig"}). Immunohistochemical studies showed that CK7 and CD10 staining were positive but that the CK20 staining was negative. After one and a half months in our department, she recovered uneventfully and was transferred to the division of medical oncology for chemotherapy. Chemotherapy, with regimen of bleomycin, etoposide and cisplatin, was arranged but pancytopenia with nosocomial infection was noted after the chemotherapy. Due to the poor response to systemic chemotherapy, hospice care was suggested and she was referred to the previous medical center.

![**(A) These cells with local glandular and squamoid differentiation were noted in the carcinomatous component (100×)**. (B) The bizarre tumor giant cell was noted in the carcinomatous component (arrow; 400x). (C) The patternless oval to spindled neoplastic cells was noted in the sarcomatous component (200x).](1752-1947-5-15-2){#F2}

Discussion
==========

MMMT arising from the female genital tract is a rare disease, comprising less than 1% of all gynecological malignancies, and MMMT of extragenital origin is even rarer. MMMT arises from the Müllerian system which develops to form the fallopian tubes, uterus and the upper portion of the vagina and often occurs in menopausal women. Since histological evaluation shows both carcinoma (epithelial) and sarcoma (mesenchymal) components, this disorder is also named carcinosarcoma. MMMT is classified into homologous or heterologous according to the sarcomatous component. Extragenital MMMT can occur at any site of peritoneum and is one type of primary peritoneal carcinomas (PPC) which was first described by Swerdlow in 1959 \[[@B2]\]. It has the characteristics of involvement in the peritoneum by carcinoma without an obvious primary site \[[@B3]\].

The majority of PPCs present in pathology as serous papillary carcinomas, as well as peritoneal mixed epithelial carcinomas, while the extragenital MMMTs are rarely reported. PPC is a rare cancer closely related to epithelial ovarian cancer and develops in cells from the lining of the pelvis and abdomen (peritoneum). These cells are similar to the cells on the surface of the ovaries. Like ovarian cancer, PPC tends to spread along the surface of the pelvis and abdomen. Symptoms of patients with PPC are similar to those with ovarian cancer, including abdominal pain or bloating, nausea, vomiting, indigestion and change in bowel habits. Women with PPC are usually treated similarly to those with widespread ovarian cancer. The therapeutic modalities include cytoreductive surgery as much as possible, followed by the same chemotherapy regimen administrated for ovarian cancer. Look *et al.* asserted that optimal cytoreduction could significantly improve the prognosis of patients \[[@B4]\]. However, PPC is of multifocal origin, which is in contrast to ovarian cancer, and usually infiltrates the peritoneal lining surface. Consequently, cytoreductive surgery is not always optimal and this therapeutic modality needs to be evaluated in order to determine whether it is an appropriate treatment for PPC.

Most PPCs are serous papillary adenocarcinomas with a relatively good prognosis but the primary peritoneal MMMT, a rare type of PPC, usually has an unfavorable outcome according to the previous literature \[[@B5]\]. MMMT of extragenital origin was first reported by Ober and Black in 1955 \[[@B6]\] and, until now, only 48 cases have been reported in the English literature. It has been reported to have arisen from the peritoneum, mesentery, omentum, spleen, diaphragm and retroperitoneum. Among all the reported cases, the majority were menopausal women with a median age of 62.8 years (range 33-87 years). Sixteen of the 49 patients (32.7%) presented with synchronous or metachronous malignancies including colonic (three cases), ovarian (six cases including the present case), fallopian tubal (three cases), endometrial (two), cervical (one) and one synchronous serous carcinoma of the peritoneum. Due to a high incidence of synchronous or metachronous colonic cancer or gynecologic malignancy originating from the Müllerian duct, clinicians should carefully check the genital tract in detail during the resection of primary MMMT.

Little information about the management of extragenital MMMT is available. All suggestions for the treatment extragenital MMMT are based on individual cases. Treatments including cytoreductive surgery and chemotherapy have been reported. Surgical management is usually mandatory due to the clinical presentation caused by the mass effect. However, a radical surgical treatment is often obtained with difficulty. It seems that chemotherapy is more important than surgical treatment and the treatment choice of MMMT is similar to that of genital MMMT.

There are several reports regarding platinum-based chemotherapy activity against MMMT of the ovary. Simon *et al.* reported a patient with MMMT of the ovary who had a suboptimal response to single-agent cisplatin chemotherapy but who demonstrated a complete response with ifosfamide, mesna, Adriamycin (doxorubicin) and dacarbazine \[[@B7]\]. Paclitaxel/carboplatin (PC) or platinum/ifosfamide (PI) has been used for the chemotherapy of ovarian MMMT \[[@B8]\]. The median survival time of patients receiving PC was 19 months. One patient receiving PC as first-line treatment demonstrated a complete response and was free of disease after 33 months. The median survival time of patients managed with PI was 23 months. Three patients with suboptimal disease demonstrated complete response after receiving PI. This study showed the potential activity of PC in MMMT of the ovaries should be further explored.

The role of radiotherapy remains controversial. When a patient presents with a grossly residual tumor, radiotherapy may be considered. Garamvoelgyi *et al.* reported a patient who received postoperative radiotherapy and survived for eight months \[[@B9]\]. Conversely, other authors consider that extragenital MMMT is one kind of PPC and is similar to ovarian epithelial tumor. Muller *et al.* reported six cases of metastasized MMMTs receiving cytoreductive surgery plus intraperitoneal hyperthermic perfusion and adjuvant treatment of CDDP (cis-diamminedichloroplatinum), mitomycin and ifosfamide applied via intraaortic catheter \[[@B10]\]. Four patients were found with no evidence of disease after two, four, 14, and 19 months, respectively. Thus, complete cytoreduction plus hyperthermic peritoneal perfusion plus adjuvant chemotherapy seems to be an effective treatment for recurrent or metastatic MMMT.

A similar case of MMMT of mesenteric origin was reported by Ma *et al.*\[[@B1]\]. The patient died of extensive metastasis 30 months after the diagnosis of MMMT. She received six courses of chemotherapy, including ifosfamide, VP-16 and carboplatin, as well as eight courses of Phyxol (paclitaxel) and cisplatin.

Recently, it has been demonstrated that the presence of BRCA mutations may predispose to primary peritoneal cancers and this neoplasm could be a part of the hereditary breast and ovary cancer syndrome \[[@B11]\]. Immunohistochemical studies, it is suggested that expression of CD10 should be examined - it may be one of the characteristics of MMMT \[[@B12],[@B13]\]. However, the significance of CD10 expression needs to be elucidated by further studies. Our patient\'s tumor also had an expression of CD10. Regarding the histological component in MMMT, Ozguroglu *et al.* investigated the role of carcinomatous and sarcomatous components on the response to chemotherapy and disease outcome. It also observed that patients with a predominating carcinomatous component had a higher therapeutic response rate (87.5%) than those with a predominating sarcomatous component (66.6%) \[[@B14]\].

Conclusion
==========

Extragenital MMMT is extremely rare and has a poor prognosis due to its aggressive biological behavior. Synchronous or metachronous gynecologic tumors often exist and a detailed examination of the genital tract must be made before and during the operation. Moreover, improved survival times would probably be obtained if accurate diagnoses and aggressive treatment, including cytoreductive surgery and chemotherapy, are applied early
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